Weekly Immune Digest
As an introduction to this new topic on our website, we will select relevant articles in the immunotherapy and immune-biomarker field, just for your interest and on a weekly basis.
At your service!
- Combined PARP and PD-1 inhibition was no better than anti-androgen therapy for unselected patients with previously treated mCRPC enrolled the KEYLYNK-010 phase 3 study.
In a retrospective analysis of patients with mCRPC, immune checkpoint inhibition was more effective than taxane chemotherapy for the 6% of patients with tumour mutation burden >10 mutations/Mb, otherwise taxanes were more effective.
A phase 3 study of combined PD-1 and PARP inhibition (pembrolizumab + olaparib) has been terminated due to lack of efficacy; the trial did not preselect patients with PARP-sensitising HR gene mutations.
- A window study in ovarian cancer sheds light on the failure of IDO1 inhibitors in clinical trials: metabolic rewiring of the immune microenvironment in IDO1 inhibitor exposed tumours resulted in bypass suppression of T cell activity.
- The US-based NCI-MATCH study has opened a new arm to study combined inhibition of PD-1 and LAG-3 in patients with microsatellite unstable tumours who have failed anti-PD-(L)1 therapy.
- The FDA have approved combined PD-1/LAG-3 inhibition in advanced melanoma, based on improved PFS versus PD-1 inhibition alone in the RELATIVITY-047 phase 3 trial.
- European regulator CHMP has taken a more conservation view than the FDA to pembrolizumab (anti-PD1) in microsatellite unstable disease, restricting its recommendation to MSI+ colorectal, endometrial, gastric, small bowel & biliary cancers.
- A new study based on five melanoma cohorts uncovers complexity in the role of the gut microbiome in predicting response to immune checkpoint inhibition, with cohort-dependent effects complicating response prediction.